Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders acquired 4,400 call options on the company. This represents an increase of approximately 37% compared to the typical volume of 3,206 call options.
Analyst Upgrades and Downgrades
A number of research firms have commented on CAPR. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.
Read Our Latest Analysis on Capricor Therapeutics
Institutional Investors Weigh In On Capricor Therapeutics
Capricor Therapeutics Stock Performance
Shares of NASDAQ:CAPR opened at $13.70 on Wednesday. The stock has a market capitalization of $622.94 million, a price-to-earnings ratio of -12.92 and a beta of 4.08. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a 50 day moving average price of $14.41 and a 200 day moving average price of $13.87.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More
- Five stocks we like better than Capricor Therapeutics
- What is MarketRank™? How to Use it
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Tesla Stock: Finding a Bottom May Take Time
- How to Read Stock Charts for Beginners
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.